Close Menu

NEW YORK – Qiagen and Inovio Pharmaceuticals are collaborating to develop a companion diagnostic to guide clinical decision making related to Inovio's DNA-based immunotherapy for cervical dysplasia caused by human papillomavirus.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.